ARPA-H’s Renee Wegrzyn: “Success, for us, is that something translates into the real world.”

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown.

January 10, 2025

DoD Ovarian Research Program FY25 anticipated funding opportunities

The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.

January 10, 2025

Vol.51 No.01

In Brief

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.

November 22, 2024

Vol.50 No.44

In Brief

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer

Funding Opportunities

DOD Glioblastoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

September 20, 2024

Vol.50 No.35

ARPA-H’s Renee Wegrzyn: “Success, for us, is that something translates into the real world.”

YOU MAY BE INTERESTED IN

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

DoD Ovarian Research Program FY25 anticipated funding opportunities

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

Renew today!

Subscriber content

Never miss an issue!

Login

ARPA-H’s Renee Wegrzyn: “Success, for us, is that something translates into the real world.”

YOU MAY BE INTERESTED IN

Pediatric cancer research cut from spending legislation at last minuteRepublicans quietly removed hard-won pediatric cancer bills

DoD Ovarian Research Program FY25 anticipated funding opportunities

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

Never miss an issue!

Login

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills